Edition:
United Kingdom

Vical Inc (VICL.OQ)

VICL.OQ on NASDAQ Stock Exchange Capital Market

1.29USD
17 Aug 2018
Change (% chg)

$-0.04 (-3.01%)
Prev Close
$1.33
Open
$1.32
Day's High
$1.32
Day's Low
$1.29
Volume
10,437
Avg. Vol
33,370
52-wk High
$3.69
52-wk Low
$1.03

Latest Key Developments (Source: Significant Developments)

Vical Announces Strategic Review
Thursday, 19 Jul 2018 

July 19 (Reuters) - Vical Inc ::VICAL ANNOUNCES REVIEW OF POTENTIAL STRATEGIC TRANSACTIONS.VICAL INC - DIRECTORS PLANS TO EXPLORE A RANGE OF STRATEGIC OPTIONS TO ENHANCE SHAREHOLDER VALUE.VICAL INC - HS RETAINED MTS HEALTH PARTNERS, L.P. AS FINANCIAL ADVISOR TO ASSIST IN STRATEGIC REVIEW PROCESS.VICAL INC - VICAL IS CURRENTLY DEVELOPING ITS NOVEL ANTI-FUNGAL DRUG VL-2397.VICAL INC - ANTICIPATES ENDING 2018 WITH MINIMUM OF $40 MILLION.VICAL - IN ABSENCE OF STRATEGIC DEAL, BELIEVES BALANCE OF $40 MILLION TO BE SUFFICIENT TO FUND OPERATIONS THROUGH TOP-LINE DATA FROM PHASE 2 PROGRAM.  Full Article

‍Stonepine Capital Management reports 6.6 pct passive stake in Vical
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Vical Inc :‍Stonepine Capital Management Llc reports 6.6 percent passive stake in Vical Inc as on November 8, 2017 - SEC filing​.  Full Article

Vical Incorporated announces pricing of $25 mln underwritten public offering of common stock
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Vical Inc :Vical Incorporated announces pricing of $25 million underwritten public offering of common stock.Says public offering of 14.3 million common shares priced at $1.75per share.  Full Article

VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON TREATMENT FOR CHRONIC HEPATITIS B INFECTION
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Vical Inc ::VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON A TREATMENT FOR CHRONIC HEPATITIS B INFECTION.‍INITIAL STAGE OF PROGRAM WILL BE TO DEMONSTRATE PRECLINICAL PROOF OF CONCEPT FOR INHIBITING HBV INFECTION IN HUMAN LIVER MODEL IN H2 2018​.‍ANGES HAS PROVIDED PARTIAL FUNDING FOR INITIAL STAGE OF PROGRAM​.‍IF INITIAL STAGE OF PROGRAM IS SUCCESSFUL, VICAL EXPECTS THAT ANGES WILL CONTINUE TO PARTICIPATE IN FUNDING OF PROGRAM ​.‍ANGES GRANTED RIGHT OF FIRST REFUSAL TO NEGOTIATE WITH CO FOR EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE HEPATITIS B THERAPY IN JAPAN​.  Full Article

Vical reports Q3 loss per share $0.27
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Vical Inc :Vical reports third quarter 2017 financial and operational results.Q3 loss per share $0.27.Q3 revenue $3.2 million versus $2.6 million.  Full Article

Vical Inc files for common stock offering of up to $23.0 mln
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Vical Inc :Vical Inc files for common stock offering of up to $23.0 million - SEC filing‍​.  Full Article

Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Vical Inc :Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial.Vical Inc - ‍Astellas Pharma Inc. expects top-line data to be available in Q1 of 2018​.Vical Inc - continues to provide Astellas with development, regulatory and manufacturing support for program​.  Full Article

BRIEF-Vical Reports Q1 Loss Per Share $0.29

* VICAL REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATIONAL RESULTS